Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.
How this was made
The 30-second read
Why it matters
This PR bundles (1) additional Actimab-A IP via issued patents and allowed/pre-grant applications, (2) an IND amendment adding a manufacturer to broaden supply and flexibility, and (3) an NYSE American listing compliance plan acceptance that extends the plan period through Nov. 27, 2027.
Market read
For traders, the most actionable elements are the accepted NYSE compliance plan (reducing delisting tail risk) and the operational step of adding a manufacturer ahead of 2H 2026 to 2027 clinical milestones.
What to watch
The NYSE plan reduces delisting risk but still requires ongoing compliance; any manufacturing delays or IND/clinical timing slippage could offset the positive operational framing.
Background
Actinium’s Actimab-A program targets myeloid-derived suppressor cells (MDSCs) and is being developed across hematologic malignancies (AML, MDS) and solid tumors, with development supported via CRADA with the NCI.
Ticker impact
Actinium disclosed newly acquired Actimab-A patents, added an IND manufacturer to expand capacity, and received NYSE American compliance plan acceptance through Nov. 27, 2027.
Near-term upside bias from the NYSE listing reassurance and operational ramp narrative, with follow-through dependent on 2H 2026 to 2027 clinical milestone delivery.
The article provides concrete, time-bounded disclosures (patent issuances, IND amendment with an additional manufacturer, and an accepted listing compliance plan) but no trial results or financial guidance, limiting magnitude and durability.
Market effects
Supports the targeted radiotherapies narrative by highlighting IP accumulation and manufacturing scaling, but does not introduce a sector-wide regulatory or reimbursement change.
Primarily US microcap/small-cap sentiment via NYSE American listing compliance, with limited spillover beyond the name.
Patent filings span US, Canada, Europe, and other jurisdictions, but the update is company-specific and not a global policy shift.
Counterpoint
Patent and manufacturing updates may not translate into near-term valuation without concrete clinical efficacy/safety data and manufacturing qualification milestones.
Key entities
- companyActinium Pharmaceuticals, Inc.
Targeted radiotherapies developer; subject of the patent, manufacturing, and NYSE listing compliance updates.
- programActimab-A
Radiotherapy backbone targeting MDSCs, with patent activity and manufacturing/IND updates described in the release.
- regulatorNYSE Regulation
Accepted Actinium’s plan to regain compliance with NYSE American continued listing standards.
- partnerNational Cancer Institute (NCI)
CRADA partner referenced for studies supplied by the additional IND manufacturer.
